Skip to main content
Top
Published in: Medical Oncology 1/2011

01-12-2011 | Original paper

Biochemical, pathological and oncological relevance of Gb3Cer receptor

Authors: D. Đevenica, V. Čikeš Čulić, A. Vuica, A. Markotić

Published in: Medical Oncology | Special Issue 1/2011

Login to get access

Abstract

Glycosphingolipids are amphipathic molecules composed of hydrophilic oligosaccharide chain and a hydrophobic ceramide part, located primarily in the membrane microdomains of animal cells. Their oligosaccharide chains make them excellent candidates for the cell surface recognition molecules. Natural glycosphingolipid, globotriaosylceramide (Gal α1-4, Gal β1-4, Glc β1-1, ceramide), is also called CD77 and its expression was previously associated with proliferating centroblasts undergoing somatic hypermutation, but it has been demonstrate that globotriaosylceramide is not a reliable marker to discriminate human centroblasts from centrocytes. Globotriaosylceramide constitutes rare P k blood group antigen on erythrocytes, and it is also known as Burkitt’s lymphoma antigen. On endothelial cells, globotriaosylceramide plays as the receptor for bacterial toxins of the Shiga family, also called verotoxins. Precise biological function and significance of globotriaosylceramide expression on endothelial cells remains to be the subject of many studies and it is believed globotriaosylceramide represents an example of a glycolipid antigen able to transduce a signal leading to apoptosis. In past decade, cancer researches put a great afford in determining new therapeutic agents such as bacterial toxins against tumor malignancies. Reports have demonstrated that verotoxin-1 induces apoptosis in solid tumor cell lines expressing globotriaosylceramide such as astrocytoma, renal cell carcinoma, colon cancer and breast cancer due to verotoxin-1 high specificity and apoptosis-inducing properties, and therefore, it is suggested to be an anticancer agent. Verotoxins have been investigated weather they could reduce treatment side-effects and toxicity to normal tissues and become a new oncological tool in cancer labeling.
Literature
1.
go back to reference Hakomori SI. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J. 2000;17:143–51.PubMed Hakomori SI. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J. 2000;17:143–51.PubMed
2.
go back to reference Sonnino S, Prinetti A, Mauri L, Chigorno V, Tettamanti G. Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem Rev. 2006;106:2111–25.PubMed Sonnino S, Prinetti A, Mauri L, Chigorno V, Tettamanti G. Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem Rev. 2006;106:2111–25.PubMed
3.
go back to reference Fantini J, Maresca M, Hammache D, Yahi N, Delézay O. Glycosphingolipid (GSL) microdomains as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: activation of signal transduction pathways and perturbations of intestinal absorption and secretion. Glycoconj J. 2001;17:173–9. Fantini J, Maresca M, Hammache D, Yahi N, Delézay O. Glycosphingolipid (GSL) microdomains as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: activation of signal transduction pathways and perturbations of intestinal absorption and secretion. Glycoconj J. 2001;17:173–9.
4.
go back to reference Stults CL, Sweeley CC, Macher BA. Glycosphingolipids: structure, biological source, and properties. Method Enzymol. 1989;179:167–214. Stults CL, Sweeley CC, Macher BA. Glycosphingolipids: structure, biological source, and properties. Method Enzymol. 1989;179:167–214.
5.
go back to reference Schnaar RL. Glycosphingolipids in cell surface recognition. Glycobiology. 1991;1:477–85.PubMed Schnaar RL. Glycosphingolipids in cell surface recognition. Glycobiology. 1991;1:477–85.PubMed
6.
go back to reference Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 1996;4:147–53.PubMed Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 1996;4:147–53.PubMed
7.
go back to reference Konowalchuk J, Dickie N, Stavric S, Speirs JI. Properties of an Escherichia coli cytotoxin. Infect Immun. 1978;20:575–7.PubMed Konowalchuk J, Dickie N, Stavric S, Speirs JI. Properties of an Escherichia coli cytotoxin. Infect Immun. 1978;20:575–7.PubMed
9.
go back to reference Boyd B, et al. Lipid modulation of glycolipid receptor function. Eur J Biochem. 1994;223:873–8.PubMed Boyd B, et al. Lipid modulation of glycolipid receptor function. Eur J Biochem. 1994;223:873–8.PubMed
10.
go back to reference Kiarash A, et al. Glycosphingolipid receptor function is modified by fatty acid content. J Biol Chem. 1994;269:11138–46.PubMed Kiarash A, et al. Glycosphingolipid receptor function is modified by fatty acid content. J Biol Chem. 1994;269:11138–46.PubMed
11.
go back to reference Lingwood CA. Aglycone modulation of glycolipid receptor function. Glycoconj J. 1996;13:495–503.PubMed Lingwood CA. Aglycone modulation of glycolipid receptor function. Glycoconj J. 1996;13:495–503.PubMed
12.
go back to reference Arab S, Lingwood CA. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty isoform traffic. J Cell Physiol. 1998;177:646–60.PubMed Arab S, Lingwood CA. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty isoform traffic. J Cell Physiol. 1998;177:646–60.PubMed
13.
go back to reference Ling H, et al. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998;37:1777–88.PubMed Ling H, et al. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998;37:1777–88.PubMed
14.
go back to reference Sandvig K, van Deurs B. Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J. 2000;19:5943–50.PubMed Sandvig K, van Deurs B. Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J. 2000;19:5943–50.PubMed
15.
go back to reference Garred O, van Deurs B, Sandvig K. Furin-induced cleavage and activation of Shiga toxin. J Biol Chem. 1995;270:10817–21.PubMed Garred O, van Deurs B, Sandvig K. Furin-induced cleavage and activation of Shiga toxin. J Biol Chem. 1995;270:10817–21.PubMed
16.
go back to reference Endo Y, et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and Shiga toxin on eukaryotic ribosomes. Eur J Biochem. 1988;171:45–50.PubMed Endo Y, et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and Shiga toxin on eukaryotic ribosomes. Eur J Biochem. 1988;171:45–50.PubMed
17.
go back to reference Mangeney M, et al. Apoptosis induced in Burkitt’s lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993;53:5314–9.PubMed Mangeney M, et al. Apoptosis induced in Burkitt’s lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993;53:5314–9.PubMed
18.
go back to reference Fan J, Sammalkorpi M, Haataja M. Formation and regulation of lipid microdomains in cell membranes: theory, modeling, and speculation. FEBS Lett. 2010;584:1678–84.PubMed Fan J, Sammalkorpi M, Haataja M. Formation and regulation of lipid microdomains in cell membranes: theory, modeling, and speculation. FEBS Lett. 2010;584:1678–84.PubMed
19.
go back to reference Gaus K, Chklovskaia E, Fazekas de Groth B, Jessup W, Harder T. Condensation of the plasma membrane at the site of T lymphocyte activation. J Cell Biol. 2005;171:121–31.PubMed Gaus K, Chklovskaia E, Fazekas de Groth B, Jessup W, Harder T. Condensation of the plasma membrane at the site of T lymphocyte activation. J Cell Biol. 2005;171:121–31.PubMed
20.
go back to reference Tavano R, et al. CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse. Nat Cell Biol. 2006;8:1270–6.PubMed Tavano R, et al. CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse. Nat Cell Biol. 2006;8:1270–6.PubMed
21.
go back to reference Chinnapen DJ, Chinnapen H, Saslowsky D, Lencer WI. Rafting with cholera toxin: endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol Lett. 2007;266:129–37.PubMed Chinnapen DJ, Chinnapen H, Saslowsky D, Lencer WI. Rafting with cholera toxin: endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol Lett. 2007;266:129–37.PubMed
22.
go back to reference Kalisiak A, Minniti JG, Oosterwijk E, Old LJ, Scheinberg DA. Neutral glycosphingolipid expression in B-cell neoplasms. Int J Cancer. 1991;49:837–45.PubMed Kalisiak A, Minniti JG, Oosterwijk E, Old LJ, Scheinberg DA. Neutral glycosphingolipid expression in B-cell neoplasms. Int J Cancer. 1991;49:837–45.PubMed
23.
go back to reference Sandvig K, et al. Pathways followed by ricin and Shiga toxin into cells. Histochem Cell Biol. 2002;117:131–41.PubMed Sandvig K, et al. Pathways followed by ricin and Shiga toxin into cells. Histochem Cell Biol. 2002;117:131–41.PubMed
24.
go back to reference Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol. 2006;7:568–79.PubMed Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol. 2006;7:568–79.PubMed
25.
go back to reference Römer W, et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature. 2007;450:670–5.PubMed Römer W, et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature. 2007;450:670–5.PubMed
26.
go back to reference Mori T, et al. Globotriaosyl ceramide (CD77/Gb3) in the glycolipidenriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating Lyn kinase activity in human B cells. Exp Hematol. 2000;28:1260–8.PubMed Mori T, et al. Globotriaosyl ceramide (CD77/Gb3) in the glycolipidenriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating Lyn kinase activity in human B cells. Exp Hematol. 2000;28:1260–8.PubMed
27.
go back to reference Katagiri YU, et al. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem. 1999;274:35278–82.PubMed Katagiri YU, et al. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem. 1999;274:35278–82.PubMed
28.
go back to reference Falguières T, et al. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent resistant membranes. Mol Biol Cell. 2001;12:2453–68.PubMed Falguières T, et al. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent resistant membranes. Mol Biol Cell. 2001;12:2453–68.PubMed
29.
go back to reference Kovbasnjuk O, et al. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J Cell Sci. 2001;114:4025–31.PubMed Kovbasnjuk O, et al. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J Cell Sci. 2001;114:4025–31.PubMed
30.
go back to reference Lencer WI, Saslowsky D. Raft trafficking of AB5 subunit bacterial toxins. Biochim Biophys Acta. 2005;1746:314–21.PubMed Lencer WI, Saslowsky D. Raft trafficking of AB5 subunit bacterial toxins. Biochim Biophys Acta. 2005;1746:314–21.PubMed
31.
go back to reference Tam P, Lingwood C. Membrane-cytosolic translocation of verotoxin A1-subunit in target cells. Microbiology. 2007;153:2700–10.PubMed Tam P, Lingwood C. Membrane-cytosolic translocation of verotoxin A1-subunit in target cells. Microbiology. 2007;153:2700–10.PubMed
32.
go back to reference Römer W, et al. Actin dynamics drive membrane reorganization and scission in clathrin-independent endocytosis. Cell. 2010;140:540–53.PubMed Römer W, et al. Actin dynamics drive membrane reorganization and scission in clathrin-independent endocytosis. Cell. 2010;140:540–53.PubMed
33.
go back to reference Binnington B, Lingwood D, Nutikka A, Lingwood CA. Effect of globotriaosyl ceramide fatty acid a-hydroxylation on the binding by verotoxin 1 and verotoxin 2. Neurochem Res. 2002;27:807–13.PubMed Binnington B, Lingwood D, Nutikka A, Lingwood CA. Effect of globotriaosyl ceramide fatty acid a-hydroxylation on the binding by verotoxin 1 and verotoxin 2. Neurochem Res. 2002;27:807–13.PubMed
34.
go back to reference Newburg D, et al. Susceptibility to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns. J Infect Dis. 1993;168:476–9.PubMed Newburg D, et al. Susceptibility to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns. J Infect Dis. 1993;168:476–9.PubMed
35.
go back to reference Lingwood CA. Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia. Biosci Rep. 1999;19:345–54.PubMed Lingwood CA. Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia. Biosci Rep. 1999;19:345–54.PubMed
36.
go back to reference Kiguchi K, et al. Characteristic expression of globotriaosyl ceramide in human ovarian carcinomaderived cells with anticancer drug resistance. Cancer Sci. 2006;97:1321–6.PubMed Kiguchi K, et al. Characteristic expression of globotriaosyl ceramide in human ovarian carcinomaderived cells with anticancer drug resistance. Cancer Sci. 2006;97:1321–6.PubMed
37.
go back to reference Sandvig K, et al. Retrograde transport from the golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol. 1994;126:53–64.PubMed Sandvig K, et al. Retrograde transport from the golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol. 1994;126:53–64.PubMed
38.
go back to reference Tam P, et al. Differential intracellular trafficking and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies. J Cell Physiol. 2008;216:750–63.PubMed Tam P, et al. Differential intracellular trafficking and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies. J Cell Physiol. 2008;216:750–63.PubMed
39.
go back to reference Burger K, Gimpl G, Fahrenholz F. Regulation of receptor function by cholesterol. Cell Mol Life Sci. 2000;57:1577–92.PubMed Burger K, Gimpl G, Fahrenholz F. Regulation of receptor function by cholesterol. Cell Mol Life Sci. 2000;57:1577–92.PubMed
40.
go back to reference Chark D, Nutikka A, Trusevych N, Kuzmina J, Lingwood C. Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody. Eur J Bioch. 2004;271:405–17. Chark D, Nutikka A, Trusevych N, Kuzmina J, Lingwood C. Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody. Eur J Bioch. 2004;271:405–17.
41.
go back to reference Smith DC, et al. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol Biol Cell. 2006;17:1375–87.PubMed Smith DC, et al. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol Biol Cell. 2006;17:1375–87.PubMed
42.
go back to reference Hoey DEE, Currie C, Lingwood CA, Gally DL, Smith DGE. Binding of verotoxin 1 to primary intestinal epithelial cells expressing Gb3 results in trafficking of toxin to lysosomal compartments. Cell Microbiol. 2003;5:85–97.PubMed Hoey DEE, Currie C, Lingwood CA, Gally DL, Smith DGE. Binding of verotoxin 1 to primary intestinal epithelial cells expressing Gb3 results in trafficking of toxin to lysosomal compartments. Cell Microbiol. 2003;5:85–97.PubMed
43.
go back to reference Khine AA, Firtel M, Lingwood CA. CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. J Cell Physiol. 1998;176:281–92.PubMed Khine AA, Firtel M, Lingwood CA. CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. J Cell Physiol. 1998;176:281–92.PubMed
44.
go back to reference Maloney MD, Lingwood CA. CD19 Has a potential CD77 (Globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med. 1994;180:191–201.PubMed Maloney MD, Lingwood CA. CD19 Has a potential CD77 (Globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med. 1994;180:191–201.PubMed
45.
go back to reference Obrig TG, et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun. 1988;56:2373–8.PubMed Obrig TG, et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun. 1988;56:2373–8.PubMed
46.
go back to reference Ohmi K, Kiyokawa N, Takeda T, Fujimoto J. Human microvascular endothelial cells are strongly sensitive to Shiga toxin. Biochem Biophys Res Commun. 1998;251:137–41.PubMed Ohmi K, Kiyokawa N, Takeda T, Fujimoto J. Human microvascular endothelial cells are strongly sensitive to Shiga toxin. Biochem Biophys Res Commun. 1998;251:137–41.PubMed
47.
go back to reference Holgersson J, Jovall PA, Breimer ME. Glycosphingolipids of human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. J Biochem. 1991;110:120–31.PubMed Holgersson J, Jovall PA, Breimer ME. Glycosphingolipids of human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. J Biochem. 1991;110:120–31.PubMed
48.
go back to reference Schuller S, Frankel G, Phillips AD. Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture. Cell Microbiol. 2004;6:289–301.PubMed Schuller S, Frankel G, Phillips AD. Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture. Cell Microbiol. 2004;6:289–301.PubMed
49.
go back to reference Ramegowda B, Samuel JE, Tesh VL. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J Infect Dis. 1999;180:1205–13.PubMed Ramegowda B, Samuel JE, Tesh VL. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J Infect Dis. 1999;180:1205–13.PubMed
50.
go back to reference Eisenhauer PE, et al. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun. 2001;69:1889–94.PubMed Eisenhauer PE, et al. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun. 2001;69:1889–94.PubMed
51.
go back to reference Stricklett PK, Hughes AK, Ergonul Z, Kohan DE. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis. 2002;186:976–82.PubMed Stricklett PK, Hughes AK, Ergonul Z, Kohan DE. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis. 2002;186:976–82.PubMed
52.
go back to reference Ergonul Z, Hughes AK, Kohan DE. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin. J Infect Dis. 2003;187:154–8.PubMed Ergonul Z, Hughes AK, Kohan DE. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin. J Infect Dis. 2003;187:154–8.PubMed
53.
go back to reference Uchida H, et al. Shiga toxins induce apoptosis in pulmonary epithelium–derived cells. J Infect Dis. 1999;180:1902–11.PubMed Uchida H, et al. Shiga toxins induce apoptosis in pulmonary epithelium–derived cells. J Infect Dis. 1999;180:1902–11.PubMed
54.
go back to reference Takahashi K, Funata N, Ikuta F, Sato S. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J Neuroinflamm. 2008;5:11–23. Takahashi K, Funata N, Ikuta F, Sato S. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J Neuroinflamm. 2008;5:11–23.
55.
go back to reference De Rosa MF, et al. Inhibition of multidrug resistance by adamantylgb3, a globotriasylceramide analog. J Biol Chem. 2008;283:4501–11.PubMed De Rosa MF, et al. Inhibition of multidrug resistance by adamantylgb3, a globotriasylceramide analog. J Biol Chem. 2008;283:4501–11.PubMed
56.
go back to reference Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005;94:312–8.PubMed Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005;94:312–8.PubMed
57.
go back to reference Nakao H, Takeda T. Escherichia coli Shiga toxin. J Nat Toxins. 2000;9:299–313.PubMed Nakao H, Takeda T. Escherichia coli Shiga toxin. J Nat Toxins. 2000;9:299–313.PubMed
58.
go back to reference Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic: uremic syndrome. Semin Thromb Hemost. 2001;27:207–13.PubMed Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic: uremic syndrome. Semin Thromb Hemost. 2001;27:207–13.PubMed
59.
go back to reference Forsyth KD, et al. Neutrophil-mediated endothelial injury in haemolytic uraemic syndrome. Lancet. 1989;2:411–4.PubMed Forsyth KD, et al. Neutrophil-mediated endothelial injury in haemolytic uraemic syndrome. Lancet. 1989;2:411–4.PubMed
60.
go back to reference Morigi M, et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001;98:1828–35.PubMed Morigi M, et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001;98:1828–35.PubMed
61.
go back to reference Ching JC, Jones NL, Ceponis PJ, Karmali MA, Sherman PM. Escherichia coli shiga-like toxins induce apoptosis and cleavage of poly (ADP-ribose) polymerase via in vitro activation of caspases. Infect Immun. 2002;70:4669–77.PubMed Ching JC, Jones NL, Ceponis PJ, Karmali MA, Sherman PM. Escherichia coli shiga-like toxins induce apoptosis and cleavage of poly (ADP-ribose) polymerase via in vitro activation of caspases. Infect Immun. 2002;70:4669–77.PubMed
62.
go back to reference Kiyokawa N, et al. Activation of the caspase cascade during Stx1-induced apoptosis in Burkitt’s lymphoma cells. J Cell Biochem. 2001;81:128–42.PubMed Kiyokawa N, et al. Activation of the caspase cascade during Stx1-induced apoptosis in Burkitt’s lymphoma cells. J Cell Biochem. 2001;81:128–42.PubMed
63.
go back to reference Tétaud C, et al. Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and verotoxin-1. J Biol Chem. 2003;278:45200–8.PubMed Tétaud C, et al. Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and verotoxin-1. J Biol Chem. 2003;278:45200–8.PubMed
64.
go back to reference Garibal J, Hollville É, Renouf B, Tétaud C, Wiels J. Caspase-8-mediated cleavage of Bid and protein phosphatase 2A-mediated activation of Bax is necessary for Verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells. Cell Signal. 2001;22:467–75. Garibal J, Hollville É, Renouf B, Tétaud C, Wiels J. Caspase-8-mediated cleavage of Bid and protein phosphatase 2A-mediated activation of Bax is necessary for Verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells. Cell Signal. 2001;22:467–75.
65.
go back to reference Lee SY, Cherla RP, Caliskan I, Tesh VL. Shiga toxin 1 induces apoptosis in the human myelogenous leukemia cell line THP-1 by a caspase-8-dependent, tumor necrosis factor-independent mechanism. Infect Immun. 2008;73:5115–26. Lee SY, Cherla RP, Caliskan I, Tesh VL. Shiga toxin 1 induces apoptosis in the human myelogenous leukemia cell line THP-1 by a caspase-8-dependent, tumor necrosis factor-independent mechanism. Infect Immun. 2008;73:5115–26.
66.
go back to reference Erwert RD, et al. Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb Pathog. 2003;35:87–93.PubMed Erwert RD, et al. Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb Pathog. 2003;35:87–93.PubMed
67.
go back to reference Fujii J, et al. Rapid apoptosis induced by Shiga toxin in HeLa cells. Infect Immun. 2003;71:2724–35.PubMed Fujii J, et al. Rapid apoptosis induced by Shiga toxin in HeLa cells. Infect Immun. 2003;71:2724–35.PubMed
68.
go back to reference Gariepy J. The use of Shiga-like toxin 1 in cancer therapy. Crit Rev Oncol Hematol. 2001;39:99–106.PubMed Gariepy J. The use of Shiga-like toxin 1 in cancer therapy. Crit Rev Oncol Hematol. 2001;39:99–106.PubMed
69.
go back to reference LaCasse EC, et al. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood. 1999;94:2901–10.PubMed LaCasse EC, et al. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood. 1999;94:2901–10.PubMed
70.
go back to reference Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR. The treatment of malignant meningioma with verotoxin. Neoplasia. 2002;4:304–11.PubMed Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR. The treatment of malignant meningioma with verotoxin. Neoplasia. 2002;4:304–11.PubMed
71.
go back to reference Murray LJ, Habeshaw JA, Wiels J, Greaves MF. Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer. 1985;36:561–5.PubMed Murray LJ, Habeshaw JA, Wiels J, Greaves MF. Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer. 1985;36:561–5.PubMed
72.
go back to reference Ohyama C, et al. Changes in glycolipid expression in human testicular tumor. Int J Cancer. 1990;45:1040–4.PubMed Ohyama C, et al. Changes in glycolipid expression in human testicular tumor. Int J Cancer. 1990;45:1040–4.PubMed
73.
go back to reference Johansson D, et al. Verotoxin-1 induction of apoptosis in Gb3- expressing human glioma cell lines. Cancer Biol Ther. 2006;5:1211–7.PubMed Johansson D, et al. Verotoxin-1 induction of apoptosis in Gb3- expressing human glioma cell lines. Cancer Biol Ther. 2006;5:1211–7.PubMed
74.
go back to reference Arab S, et al. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol Res. 1997;9:553–63.PubMed Arab S, et al. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol Res. 1997;9:553–63.PubMed
75.
go back to reference Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs. 2003;17:155–67.PubMed Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs. 2003;17:155–67.PubMed
76.
go back to reference Kovbasnjuk O, et al. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci USA. 2005;102:19087–92.PubMed Kovbasnjuk O, et al. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci USA. 2005;102:19087–92.PubMed
77.
go back to reference Johannes L, Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther. 2005;12:1360–8.PubMed Johannes L, Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther. 2005;12:1360–8.PubMed
78.
go back to reference Janssen KP, et al. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res. 2006;66:7230–6.PubMed Janssen KP, et al. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res. 2006;66:7230–6.PubMed
79.
go back to reference Ludwig K, et al. Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol. 2001;39:2272–9.PubMed Ludwig K, et al. Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol. 2001;39:2272–9.PubMed
80.
go back to reference Levine MM, et al. Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery. J Clin Microbiol. 1992;30:1636–41.PubMed Levine MM, et al. Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery. J Clin Microbiol. 1992;30:1636–41.PubMed
81.
go back to reference O’Brien AD, et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol. 1992;180:65–94.PubMed O’Brien AD, et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol. 1992;180:65–94.PubMed
82.
go back to reference Vingert B, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol. 2006;36:1124–35.PubMed Vingert B, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol. 2006;36:1124–35.PubMed
83.
go back to reference Haicheur N, et al. Vt B-subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I restricted presentation of peptides derived from exogenous antigens. J Immunol. 2000;165:3301–8.PubMed Haicheur N, et al. Vt B-subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I restricted presentation of peptides derived from exogenous antigens. J Immunol. 2000;165:3301–8.PubMed
84.
go back to reference Wang H, Griffiths MN, Burton DR, Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA. 2000;97:847–85.PubMed Wang H, Griffiths MN, Burton DR, Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA. 2000;97:847–85.PubMed
85.
go back to reference Haicheur N, et al. The B subunit of Shiga toxin coupled to fullsize antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol. 2003;15:1–11. Haicheur N, et al. The B subunit of Shiga toxin coupled to fullsize antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol. 2003;15:1–11.
86.
go back to reference Falguières T. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther. 2008;7:2498–508.PubMed Falguières T. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther. 2008;7:2498–508.PubMed
87.
go back to reference Viel T, et al. In vivo tumor targeting by the B-subunit of shiga toxin. Mol Imaging. 2008;7:239–47.PubMed Viel T, et al. In vivo tumor targeting by the B-subunit of shiga toxin. Mol Imaging. 2008;7:239–47.PubMed
88.
go back to reference Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002;62:832–45.PubMed Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002;62:832–45.PubMed
89.
go back to reference Imberty A, Wimmerová M, Mitchell EP, Gilboa-Garber N. Structures of the lectins from Pseudomonas aeruginosa: insight into the molecular basis for host glycan recognition. Microbes Infect. 2004;6:221–8.PubMed Imberty A, Wimmerová M, Mitchell EP, Gilboa-Garber N. Structures of the lectins from Pseudomonas aeruginosa: insight into the molecular basis for host glycan recognition. Microbes Infect. 2004;6:221–8.PubMed
90.
go back to reference Blanchard B, et al. Structural basis of the preferential binding for globo-series glycosphingolipids displayed by Pseudomonas aeruginosa lectin I. Mol Biol. 2008;383:837–53. Blanchard B, et al. Structural basis of the preferential binding for globo-series glycosphingolipids displayed by Pseudomonas aeruginosa lectin I. Mol Biol. 2008;383:837–53.
91.
go back to reference Distler U, et al. Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS ONE. 2009;4(8):e6813. Distler U, et al. Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS ONE. 2009;4(8):e6813.
92.
go back to reference Schuller S, Heuschkel R, Torrente F, Kaper JB, Phillips AD. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect. 2007;9:35–9.PubMed Schuller S, Heuschkel R, Torrente F, Kaper JB, Phillips AD. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect. 2007;9:35–9.PubMed
93.
go back to reference Ishitoya S, et al. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol. 2004;171:1309–13.PubMed Ishitoya S, et al. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol. 2004;171:1309–13.PubMed
94.
go back to reference Arab S, Rutka J, Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol Res. 1999;11:33–9.PubMed Arab S, Rutka J, Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol Res. 1999;11:33–9.PubMed
95.
go back to reference Heath-Engel HM, Lingwood CA. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis. 2003;6:129–41.PubMed Heath-Engel HM, Lingwood CA. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis. 2003;6:129–41.PubMed
96.
go back to reference Johansson D, et al. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer. 2009;9:67–76.PubMed Johansson D, et al. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer. 2009;9:67–76.PubMed
97.
go back to reference Bornkamm GW, Polack A, Eick D, Berger R, Lenoir GM. Chromosome translocations and Epstein-Barr virus in Burkitt’s lymphoma. Onkologie. 1987;10:196–204.PubMed Bornkamm GW, Polack A, Eick D, Berger R, Lenoir GM. Chromosome translocations and Epstein-Barr virus in Burkitt’s lymphoma. Onkologie. 1987;10:196–204.PubMed
98.
go back to reference Jaffe ES, et al. Burkitt’s lymphoma: a single disease with multiple variants. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Blood. 1999;3:1124. Jaffe ES, et al. Burkitt’s lymphoma: a single disease with multiple variants. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Blood. 1999;3:1124.
99.
go back to reference Gordon J, et al. CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1B chain but fail to protect against the holotoxin. Cell Death Differ. 2000;7:785–94.PubMed Gordon J, et al. CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1B chain but fail to protect against the holotoxin. Cell Death Differ. 2000;7:785–94.PubMed
100.
go back to reference Cohen A, Hannigan GE, Williams BRG, Lingwood CA. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem. 1987;262:17088–91.PubMed Cohen A, Hannigan GE, Williams BRG, Lingwood CA. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem. 1987;262:17088–91.PubMed
101.
go back to reference Wiels J, Fellous M, Tursz T. Monoclonal antibody against a Burkitt lymphoma associated antigen. Proc Natl Acad Sci USA. 1981;78:6485–9.PubMed Wiels J, Fellous M, Tursz T. Monoclonal antibody against a Burkitt lymphoma associated antigen. Proc Natl Acad Sci USA. 1981;78:6485–9.PubMed
102.
go back to reference Sakthivel R, Christensson B, Ehlin-Henriksson B, Klein G. Immunophenotypic characterization of follicle-center-cell-derived non-Hodgkin’s lymphomas. Int J Cancer. 1989;43:624–30.PubMed Sakthivel R, Christensson B, Ehlin-Henriksson B, Klein G. Immunophenotypic characterization of follicle-center-cell-derived non-Hodgkin’s lymphomas. Int J Cancer. 1989;43:624–30.PubMed
103.
go back to reference Taga S, et al. Intracellular signalling events in CD77-mediated apoptosis of Burkitt’s lymphoma cells. Blood. 1997;90:2757–67.PubMed Taga S, et al. Intracellular signalling events in CD77-mediated apoptosis of Burkitt’s lymphoma cells. Blood. 1997;90:2757–67.PubMed
104.
go back to reference Grafton G, Goodall M, Gregory CD, Gordon J. Mechanisms of antigen receptor-dependent apoptosis in human B lymphoma cell lines probed with a panel of 27 monoclonal antibodies. Cell Immunol. 1997;182:45–56.PubMed Grafton G, Goodall M, Gregory CD, Gordon J. Mechanisms of antigen receptor-dependent apoptosis in human B lymphoma cell lines probed with a panel of 27 monoclonal antibodies. Cell Immunol. 1997;182:45–56.PubMed
105.
go back to reference Michael JM, Lavin MF, Watters DJ. Resistance to radiation-induced apoptosis in Burkitt’s lymphoma cells is associated with defective ceramide signaling. Cancer Res. 1997;57:3600–5.PubMed Michael JM, Lavin MF, Watters DJ. Resistance to radiation-induced apoptosis in Burkitt’s lymphoma cells is associated with defective ceramide signaling. Cancer Res. 1997;57:3600–5.PubMed
106.
go back to reference Furukawa K, et al. Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells. J Biol Chem. 2002;277:11247–54.PubMed Furukawa K, et al. Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells. J Biol Chem. 2002;277:11247–54.PubMed
107.
go back to reference Zhang X-g, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654–63.PubMed Zhang X-g, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654–63.PubMed
108.
go back to reference Szczepek AJ, et al. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood. 1998;92:2844–55.PubMed Szczepek AJ, et al. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood. 1998;92:2844–55.PubMed
109.
go back to reference Bechtel D, Kurth J, Unkel C, Ku¨ppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood. 2005;106:4345–50.PubMed Bechtel D, Kurth J, Unkel C, Ku¨ppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood. 2005;106:4345–50.PubMed
110.
go back to reference Arbus GS, et al. Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease. Leukemia Res. 2000;24:857–64. Arbus GS, et al. Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease. Leukemia Res. 2000;24:857–64.
111.
go back to reference Craxton A, Chuang PI, Shu G, Harlan JM, Clark EA. The CD40-inducible Bcl-2 family member A1 protects B Cells from antigen receptor-mediated apoptosis. Cell Immunol. 2000;200:56–62.PubMed Craxton A, Chuang PI, Shu G, Harlan JM, Clark EA. The CD40-inducible Bcl-2 family member A1 protects B Cells from antigen receptor-mediated apoptosis. Cell Immunol. 2000;200:56–62.PubMed
112.
go back to reference Li T, Ramirez K, Palacios R. Distinct patterns of Fas cell surface expression during development of T- or B-lymphocyte lineages in normal, scid, and mutant mice lacking or overexpressing p53, bcl-2, or rag-2 genes. Cell Growth Differ. 1996;7:107–14.PubMed Li T, Ramirez K, Palacios R. Distinct patterns of Fas cell surface expression during development of T- or B-lymphocyte lineages in normal, scid, and mutant mice lacking or overexpressing p53, bcl-2, or rag-2 genes. Cell Growth Differ. 1996;7:107–14.PubMed
113.
go back to reference Ghia P, et al. Unbalanced expression of Bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood. 1998;91:224–51. Ghia P, et al. Unbalanced expression of Bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood. 1998;91:224–51.
114.
go back to reference Holder MJ, et al. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur J Immunol. 1993;23:2368–71.PubMed Holder MJ, et al. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur J Immunol. 1993;23:2368–71.PubMed
115.
go back to reference Traulle C, Coiffier B. Evolving role of rituximab in the treatment of patients with non-Hodgkin’s lymphoma. Future Oncol. 2005;1:297–306.PubMed Traulle C, Coiffier B. Evolving role of rituximab in the treatment of patients with non-Hodgkin’s lymphoma. Future Oncol. 2005;1:297–306.PubMed
116.
go back to reference Béniguel L, et al. identification of germinal center B cells in blood from HIV-infected drug-naive individuals in central Africa. Clin Dev Immunol. 2004;11:23–7.PubMed Béniguel L, et al. identification of germinal center B cells in blood from HIV-infected drug-naive individuals in central Africa. Clin Dev Immunol. 2004;11:23–7.PubMed
117.
go back to reference Ramkumar S, Sakac D, Binnington B, Branch DR, Lingwood CA. Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. Glycobiology. 2009;19:76–82.PubMed Ramkumar S, Sakac D, Binnington B, Branch DR, Lingwood CA. Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. Glycobiology. 2009;19:76–82.PubMed
Metadata
Title
Biochemical, pathological and oncological relevance of Gb3Cer receptor
Authors
D. Đevenica
V. Čikeš Čulić
A. Vuica
A. Markotić
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue Special Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9732-8

Other articles of this Special Issue 1/2011

Medical Oncology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.